Steven Cohen Verastem, Inc. Transaction History

Point72 Asset Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$1.11 - $1.68 $832,500 - $1.26 Million	-750,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$1.69 - $4.2 $9.08 Million - $22.6 Million	-5,371,043 Reduced 87.75%	750,000 $1.29 Million
Q1 2020 May 15, 2020	BUY	$1.26 - $3.38 $7.71 Million - $20.7 Million	6,121,043 New	6,121,043 $16.2 Million
Q4 2017 Feb 14, 2018	SELL	$2.99 - $4.85 $4.19 Million - $6.79 Million	-1,400,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$3.01 - $5.41 $4.21 Million - $7.57 Million	1,400,000	1,400,000 $6.58 Million

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $840M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.